IPHA analyst estimates
Innate Pharma (IPHA) analyst ratings, the average price target and its range, and every firm's latest call.
- 2 firms rate IPHA: 2 buy, 0 hold, 0 sell.
- The average price target is $6.67 from None analysts, from $4.00 to $9.00.
IPHA analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 12, 2026 | BTIG | Innate Pharma price target raised to $9 from $8 at BTIG | $9.00 |
| Aug 11, 2026 | Leerink Partners | Leerink upgrades Innate Pharma to Outperform after lacutamab deal | $4.00 |
| Aug 10, 2026 | H.C. Wainwright | Innate Pharma price target raised to $7 from $5 at H.C. Wainwright | $7.00 |
| Oct 29, 2025 | H.C. Wainwright | Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright | $5.00 |
| Sep 17, 2025 | Leerink Partners | Innate Pharma downgraded to Market Perform from Outperform at Leerink | $2.00 |